Akari Therapeutics (AKTX) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Akari Therapeutics' shares. Their AKTX share price forecasts range from $30.00 to $80.00. On average, they expect the company's stock price to reach $55.00 in the next twelve months. This suggests a possible upside of 1,427.8% from the stock's current price.
View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts.

Akari Therapeutics' stock was trading at $9.3980 on January 1st, 2023. Since then, AKTX shares have decreased by 61.7% and is now trading at $3.60.
View the best growth stocks for 2023 here.

Akari Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 7,900 shares, a decline of 24.8% from the August 15th total of 10,500 shares. Based on an average trading volume of 30,400 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company's shares are sold short.
View Akari Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our AKTX earnings forecast.

Akari Therapeutics, Plc (NASDAQ:AKTX) released its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing the consensus estimate of ($2.80) by $5.00.

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Akari Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cerity Partners LLC (0.43%).
View institutional ownership trends.

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKTX stock can currently be purchased for approximately $3.60.

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $13.39 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($7.00) on an earnings per share basis.

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.